ALYREF-mediated m 5 C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma

International Journal of Biological Sciences 2026 Open access

Read full text
Authors: Zeyi Lu, Yang Li, Ziwei Zhu, Fan Li, Yiming Ding, Lifeng Ding, Ruyue Wang, Yudong Lin, Wenqin Luo, Xudong Mao, Haohua Lu, Yejinpeng Wang
+10 more Mengxuan Li, yuanlei Chen, Zhehao Xu, Yi Lu, Qiming Zheng, Haiyun Xie, Zhenwei Zhou, Liqun Xia, Gonghui Li, Mingchao Wang
DOI: 10.7150/ijbs.131368
Cited by: 1

Abstract

C modification, promoting Cyclin A1 expression. The Cyclin A1-CDK2 complex phosphorylates p21 at Thr-57, inducing its cytoplasmic translocation and abrogating its inhibitory effect on cell cycle progression, thereby facilitating G1-S transition. Our findings uncover a critical ALYREF-Cyclin A1-p21 axis in RCC and suggest that targeting this pathway may provide novel therapeutic strategies to overcome pazopanib resistance.

Fields of Study & Subjects

Ferroptosis and cancer prognosis Prostate Cancer Treatment and Research RNA modifications and cancer

Publication details

Journal / source
International Journal of Biological Sciences
Publisher
Ivyspring International Publisher
Volume
22
Issue
12
Pages
6319–6337
Publication date
17 June 2026
Language
EN